Sujata Sridharan1, Joel Raffel2, Ashwini Nandoskar2, Chris Record2, David J Brooks2,3,4, David Owen2, David Sharp2, Paolo A Muraro2, Roger Gunn5, Richard Nicholas2. 1. Division of Brain Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, Burlington Danes Building, Du Cane Road, London, W12 0NN, UK. s.sridharan@imperial.ac.uk. 2. Division of Brain Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, Burlington Danes Building, Du Cane Road, London, W12 0NN, UK. 3. Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark. 4. Institute of Neuroscience, Newcastle upon Tyne University, Newcastle upon Tyne, UK. 5. Invicro Ltd., London, UK.
Abstract
PURPOSE: Measurements of non-displaceable binding (VND) of positron emission tomography (PET) ligands are not often made in vivo in humans because they require ligands to displace binding to target receptors and there are few readily available, safe ones to use. A technique to measure VND for ligands for the 18-kDa translocator protein (TSPO) has recently been developed which compares the total volume of distribution (VT) before and after administration of the TSPO ligand XBD173. Here, we used XBD173 with an occupancy plot to quantify VND for two TSPO radiotracers, [18F]GE-180 and [11C]PBR28, in cohorts of people with multiple sclerosis (MS). Additionally, we compared plots of subjects carrying high (HAB) or mixed binding (MAB) affinity polymorphisms of TSPO to estimate VND without receptor blockade. PROCEDURES: Twelve people with MS underwent baseline MRI and 90-min dynamic [18F]GE-180 PET or [11C]PBR28 PET (n = 6; three HAB, three MAB each). Arterial blood sampling was used to generate plasma input functions for the two-tissue compartment model. VND was calculated using two independent methods: the occupancy plot (by modelling the differences in signal post XBD173) and the polymorphism plot (by modelling the differences in signal across presence and absence of rs6971 genotypes). RESULTS: Whole brain VT (mean ± standard deviation) was 0.29 ± 0.17 ml/cm3 for [18F]GE-180 and 5.01 ± 1.88 ml/cm3 for [11C]PBR28. Using the occupancy and polymorphism plots respectively, VND for [18F]GE-180 was 0.11 ml/cm3 (95 % CI = 0.02, 0.16) and 0.20 ml/cm3 (0.16, 0.34), accounting for, on average, 55 % of VT in the whole brain. For [11C]PBR28, these values were 3.81 ml/cm3 (3.02, 4.21) and 3.49 ml/cm3 (1.38, 4.27), accounting for 67 % of average whole brain VT. CONCLUSIONS: Although VT for [18F]GE-180 is low, indicating low brain penetration, half the signal shown by MS subjects reflected specific TSPO binding. VT for [11C]PBR28 was higher and two thirds of the binding was non-specific. No brain ROIs were devoid of specific signal, further confirming that true reference tissue approaches are potentially problematic for estimating TSPO levels.
PURPOSE: Measurements of non-displaceable binding (VND) of positron emission tomography (PET) ligands are not often made in vivo in humans because they require ligands to displace binding to target receptors and there are few readily available, safe ones to use. A technique to measure VND for ligands for the 18-kDa translocator protein (TSPO) has recently been developed which compares the total volume of distribution (VT) before and after administration of the TSPO ligand XBD173. Here, we used XBD173 with an occupancy plot to quantify VND for two TSPO radiotracers, [18F]GE-180 and [11C]PBR28, in cohorts of people with multiple sclerosis (MS). Additionally, we compared plots of subjects carrying high (HAB) or mixed binding (MAB) affinity polymorphisms of TSPO to estimate VND without receptor blockade. PROCEDURES: Twelve people with MS underwent baseline MRI and 90-min dynamic [18F]GE-180 PET or [11C]PBR28 PET (n = 6; three HAB, three MAB each). Arterial blood sampling was used to generate plasma input functions for the two-tissue compartment model. VND was calculated using two independent methods: the occupancy plot (by modelling the differences in signal post XBD173) and the polymorphism plot (by modelling the differences in signal across presence and absence of rs6971 genotypes). RESULTS: Whole brain VT (mean ± standard deviation) was 0.29 ± 0.17 ml/cm3 for [18F]GE-180 and 5.01 ± 1.88 ml/cm3 for [11C]PBR28. Using the occupancy and polymorphism plots respectively, VND for [18F]GE-180 was 0.11 ml/cm3 (95 % CI = 0.02, 0.16) and 0.20 ml/cm3 (0.16, 0.34), accounting for, on average, 55 % of VT in the whole brain. For [11C]PBR28, these values were 3.81 ml/cm3 (3.02, 4.21) and 3.49 ml/cm3 (1.38, 4.27), accounting for 67 % of average whole brain VT. CONCLUSIONS: Although VT for [18F]GE-180 is low, indicating low brain penetration, half the signal shown by MS subjects reflected specific TSPO binding. VT for [11C]PBR28 was higher and two thirds of the binding was non-specific. No brain ROIs were devoid of specific signal, further confirming that true reference tissue approaches are potentially problematic for estimating TSPO levels.
Authors: Vincent J Cunningham; Eugenii A Rabiner; Mark Slifstein; Marc Laruelle; Roger N Gunn Journal: J Cereb Blood Flow Metab Date: 2009-09-09 Impact factor: 6.200
Authors: David R Owen; Owain W Howell; Sac-Pham Tang; Lisa A Wells; Idriss Bennacef; Mats Bergstrom; Roger N Gunn; Eugenii A Rabiner; Martin R Wilkins; Richard Reynolds; Paul M Matthews; Christine A Parker Journal: J Cereb Blood Flow Metab Date: 2010-04-28 Impact factor: 6.200
Authors: H Watabe; M A Channing; M G Der; H R Adams; E Jagoda; P Herscovitch; W C Eckelman; R E Carson Journal: J Cereb Blood Flow Metab Date: 2000-06 Impact factor: 6.200
Authors: Paolo Zanotti-Fregonara; Belen Pascual; Gaia Rizzo; Meixiang Yu; Neha Pal; David Beers; Randall Carter; Stanley H Appel; Nazem Atassi; Joseph C Masdeu Journal: J Nucl Med Date: 2018-01-18 Impact factor: 10.057
Authors: Vera Russmann; Matthias Brendel; Erik Mille; Angela Helm-Vicidomini; Roswitha Beck; Lisa Günther; Simon Lindner; Axel Rominger; Michael Keck; Josephine D Salvamoser; Nathalie L Albert; Peter Bartenstein; Heidrun Potschka Journal: Neuroimage Clin Date: 2017-04-05 Impact factor: 4.881
Authors: Claire Feeney; Gregory Scott; Joel Raffel; S Roberts; Christopher Coello; Amy Jolly; Graham Searle; A P Goldstone; David J Brooks; Richard S Nicholas; William Trigg; Roger N Gunn; David J Sharp Journal: Eur J Nucl Med Mol Imaging Date: 2016-06-28 Impact factor: 9.236
Authors: Nathalie L Albert; Marcus Unterrainer; Matthias Brendel; Lena Kaiser; Markus Zweckstetter; Paul Cumming; Peter Bartenstein Journal: Eur J Nucl Med Mol Imaging Date: 2019-03-02 Impact factor: 9.236
Authors: M Unterrainer; D F Fleischmann; F Vettermann; V Ruf; L Kaiser; D Nelwan; S Lindner; M Brendel; V Wenter; S Stöcklein; J Herms; V M Milenkovic; R Rupprecht; J C Tonn; C Belka; P Bartenstein; M Niyazi; N L Albert Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-05 Impact factor: 9.236
Authors: Lena Kaiser; Adrien Holzgreve; Stefanie Quach; Michael Ingrisch; Marcus Unterrainer; Franziska J Dekorsy; Simon Lindner; Viktoria Ruf; Julia Brosch-Lenz; Astrid Delker; Guido Böning; Bogdana Suchorska; Maximilian Niyazi; Christian H Wetzel; Markus J Riemenschneider; Sophia Stöcklein; Matthias Brendel; Rainer Rupprecht; Niklas Thon; Louisa von Baumgarten; Jörg-Christian Tonn; Peter Bartenstein; Sibylle Ziegler; Nathalie L Albert Journal: Cancers (Basel) Date: 2021-12-23 Impact factor: 6.639
Authors: William C Kreisl; Min-Jeong Kim; Jennifer M Coughlin; Ioline D Henter; David R Owen; Robert B Innis Journal: Lancet Neurol Date: 2020-11 Impact factor: 44.182
Authors: Franziska J Vettermann; Stefanie Harris; Julia Schmitt; Marcus Unterrainer; Simon Lindner; Boris-Stephan Rauchmann; Carla Palleis; Endy Weidinger; Leonie Beyer; Florian Eckenweber; Sebastian Schuster; Gloria Biechele; Christian Ferschmann; Vladimir M Milenkovic; Christian H Wetzel; Rainer Rupprecht; Daniel Janowitz; Katharina Buerger; Robert Perneczky; Günter U Höglinger; Johannes Levin; Christian Haass; Joerg C Tonn; Maximilian Niyazi; Peter Bartenstein; Nathalie L Albert; Matthias Brendel Journal: Life (Basel) Date: 2021-05-26